The Source — the HYDROGENYX Journal
Telomeren en H₂: Ohta-studie 2024 op 247 deelnemers
Paul Fournier
Telomeres are the protective caps of our chromosomes. Their progressive shortening is one of the most direct markers of cellular aging. Preliminary data (Ohta pilot cohort, not yet peer-reviewed) suggest a signal to be interpreted with caution — results observed in the study, not a promise of individual results.
Telomeres — a biological reminder
Each human chromosome ends with a repeated DNA structure (TTAGGG sequence repeated thousands of times) called a telomere. With each cell division, this sequence shortens slightly (50 to 200 base pairs). When telomere length reaches a critical threshold, the cell enters senescence: it stops dividing, becomes pro-inflammatory, and contributes to tissue aging.
Average telomere length declines with biological age. Several factors accelerate this decline: chronic oxidative stress, inflammation, obesity, smoking, disrupted sleep, chronic psychological stress. Conversely, moderate exercise, a Mediterranean diet, meditation, omega-3s, and deep sleep are associated with a slower telomere decline.
The discovery of the role of telomeres in aging earned Elizabeth Blackburn, Carol Greider, and Jack Szostak the Nobel Prize in Medicine in 2009. Since then, over 35,000 PubMed publications have indexed the telomere-aging relationship. Mean leukocyte telomere length (LTL) is now one of the most widely used "biological age" biomarkers in gerontology, alongside Horvath's and Levine's epigenetic clocks (PhenoAge, GrimAge).
Short telomere length for chronological age is associated with increased all-cause mortality (Cawthon 2003 meta-analysis), a +21% cardiovascular risk, a +37% dementia risk, and accelerated physical functional decline. Preserving telomere length is therefore a legitimate goal of preventive medicine in 2026.
The Ohta 2024 study — methodology
General Design
Pilot observational cohort, 247 participants, average age 56.4 years, 12-month follow-up. Distribution: 124 regular hydrogen water users (1 to 1.5 L/day, > 1 ppm verified by DPD), 123 controls matched for age, sex, BMI, smoking status.
Ohta S, et al. — preliminary data presented at conference (ISHM Tsukuba), not yet published in a peer-reviewed journal. To be interpreted with caution.
Telomere length was measured by qPCR on leukocyte DNA, a standardized method (T/S ratio) at T0, 6 months, and 12 months. Additional measurements: high-sensitivity CRP, urinary 8-OHdG (marker of oxidative DNA damage), HOMA-IR (insulin resistance), complete lipid profile.
Main results
Participants in the H₂ group showed a 22% slower telomere decline compared to controls over 12 months (p < 0.03). The effect appeared more pronounced in the subgroup with high baseline CRP (> 3 mg/L). Preliminary data from an observational cohort — results observed in the study, not a promise of individual results.
| Marker | H₂ Group | Controls | p-value |
|---|---|---|---|
| Δ T/S ratio at 12 months | −0.021 | −0.027 | 0.03 |
| Δ hs-CRP | −31% | −4% | 0.002 |
| Δ Urinary 8-OHdG | −18% | +3% | 0.001 |
| Δ HOMA-IR | −9% | −2% | 0.12 |
Interpretation
The mechanism proposed by Ohta: telomere shortening is largely mediated by oxidative stress (the guanine bases of the TTAGGG repeats are particularly susceptible to oxidation). According to the authors' hypothesis, by acting on oxidative stress and inflammation markers, H₂ could reduce the pressure on telomeres — without lengthening them. This is a research hypothesis, not demonstrated in humans.
This point is important: the study does not show telomere lengthening, but a slowing down of their decline. This is consistent with the entire literature: no known nutrient or supplement (other than experimental telomerase activators) has shown telomere lengthening in healthy adults.
Known limitations
The study is not randomized (observational cohort), which introduces selection bias. H₂ participants may have better overall health behaviors (diet, exercise). The authors controlled for BMI, self-reported physical activity, and diet, but residual confounding variables remain possible.
The effect size is moderate (22% slowing). Over 12 months, in absolute terms, the T/S ratio difference is small. Larger (1000+ participants) and longer (5+ years) cohorts would be needed to draw definitive conclusions.
No double-blind controlled randomization has yet validated these results. Several RCTs are underway (University of Pittsburgh, Tsukuba). First results expected 2027.
Finally, an important methodological point: telomere measurement by qPCR (the technique used by Ohta) has an inter-laboratory variability of 5 to 10%. More precise techniques (TRF Southern blot, FISH) are costly and not widely used. The effect size observed in Ohta 2024 (22% slowing) remains above the technical noise, but independent replication with the TRF method would be ideal.
How to read this data
These results are preliminary and observational: they describe a field of research, not an established product benefit. They do not constitute an indication or a promise of individual results.
Usage benchmark: the dosage mentioned in the cohort (1 to 1.5 L/day, > 1 ppm) corresponds to regular use. The HYDROGENYX Flask delivers 9,000 PPB (manufacturer's data), which leaves room for loss during transport and ingestion.
Duration: longevity markers are assessed over the long term; nothing replaces medical follow-up to interpret your own results.
CRP monitoring under H₂ is discussed in our article CRP and inflammation — what the research says.
Conclusion
This data does not "prove" anything about longevity. At best, it provides an exploratory signal to be confirmed. Combined with studies on oxidative stress (several hundred publications), they fuel a research hypothesis, not yet demonstrated in humans.
We await randomized trials to conclude. In the meantime, H₂ is part of a wellness approach (energy, recovery, hydration), not an anti-aging promise.
If you want to measure your own telomere trajectory, several French laboratories now offer the test (saliva kit or blood test, approximately 150 to 300 euros). You can establish a baseline and then follow up annually. Combined with intermediate markers (quarterly hs-CRP, urinary 8-OHdG), you get an overview of your oxidative stress and its long-term impact on DNA.
The HYDROGENYX Flask is a water preparation device, not a medical device. It does not prevent, treat, or cure any disease.
HYDROGENYX Flask
The hydrogen ritual, ready in 5 minutes.
Up to ~9,000 ppb of dissolved molecular hydrogen (manufacturer's data), verifiable at home with a DPD test. 400 ml, touch screen, wireless charging base included.
60-day money-back guarantee · 5-year cell warranty · 4× Klarna
The HYDROGENYX Flask is a water preparation device, not a medical device. It does not prevent, treat, or cure any disease.
To go further: the science of hydrogen · the comparison · the FAQ
